All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Dr. Jordi Esteve | EBMT 2018 | Key measures for prevention of post-transplant relapse in AML
Bookmark this article
At the 44th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, 18–21 Mar 2018, Dr. Jordi Esteve (chair of our European Steering Committee) from Hospital Clinic of Barcelona, Barcelona, ES, discusses key measures for the prevention of post-transplant relapse in acute myeloid leukemia (AML) including the use of pharmacological measures such as FLT3 inhibitors and immunological measures such as preemptive or prophylactic DLI.
Dr. Jordi Esteve | EBMT 2018 | Key measures for prevention of post-transplant relapse in AML
Your opinion matters
1 vote - 5 days left ...
Newsletter
Subscribe to get the best content related to AML delivered to your inbox